secwatch.observer — SEC 8-K summary
======================================

Issuer:     Rani Therapeutics Holdings, Inc. (RANI)
CIK:        0001856725
Form:       8-K
Filed at:   2023-05-30T23:59:59+00:00
Accession:  0000950170-23-024817
Event type: other
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Rani Therapeutics annual meeting elects all director nominees; ratifies Ernst & Young as auditor
--------------------------------------------------------------------------------

- All 8 director nominees elected with substantial support; votes for each exceeded 226M, with withheld votes under 200K.
- Ratification of Ernst & Young as independent auditor passed: 230,587,049 for, 51 against, 2,301 abstain.
- Record date March 30, 2023: 25.4M Class A shares (1 vote each) and 24.1M Class B shares (10 votes each) outstanding.
- No other proposals were considered; all matters approved as recommended by the board.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1856725/000095017023024817/0000950170-23-024817-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1856725/000095017023024817/rani-20230525.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-024817

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer